Integra Lifesciences today announced it named Mojdeh Poul as president and CEO, effective January 6, 2025.

Poul will also join the Integra board when she assumes her new role at the New Jersey–based tissue regeneration and neurological treatment technology companies in January. She succeeds Jan De Witte, who will remain president and CEO until January 6, 2025. Stuart Essig will remain as executive chair of the Integra board of directors for a limited time before returning to his non-executive chair role.

“The board and I are thrilled to welcome Mojdeh as Integra’s next president and CEO,” Essig said in a news release. “Mojdeh is a seasoned global healthcare executive who brings a wealth of knowledge and expertise in business strategy and transformation, commercial excellence, and leadership development. Her passion for building high-performance teams that navigate complexity and deliver results will be critical in driving and successfully executing our strategic and operational plans. Mojdeh’s proven track record in advancing the vision and leadership impact of the companies she has served gives me great confidence she will successfully lead Integra in its mission to set new standards of care.”

Prior to joining Integra Lifesciences, Poul was the executive VP and group president for 3M’s global healthcare business, including advanced wound care. During her time at 3M, she had global accountability for all functions such as R&D, manufacturing and commercial operations, quality and regulatory. (Earlier this year, 3M spun out its healthcare business as a new independent company called Solventum.)

Before her stint at 3M, Poul held global business leadership positions of increasing responsibility at Medtronic and Boston Scientific.

“I am honored to serve as the next president and CEO of Integra and thankful to Stuart and the board for their trust in my leadership,” Poul said. “As we work through the transition, we will remain sharply focused on executing our operational and quality compliance strategic priorities, while maximizing the potential of Integra’s leading product portfolio. I look forward to partnering with the board and working with our teams and customers to advance our products and technologies to restore patients’ lives.”